To elucidate this further, a macrophage-specific panel is being developed for melanoma, breast, and brain tumors (this panel includes antibodies to CD45, CD11b, CD16, CD14, CD68, CD163, HLA-DR, and CD66b). Here, ITGAM is linked to melanoma.